Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)

Completed · Not applicable

Conditions studied: Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis, Shoulder

In brief

The purpose of this study is to determine whether liposomal bupivacaine is effective in the management of pain following total joint arthroplasty, as compared to standard of care analgesia.

Key facts

Study ID

NCT02197273

Run by

OhioHealth

People needed

211

Starts

2014-07-01

Expected to finish

2015-10-01

Last updated by the study team

2016-10-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of osteoarthritis
• Elected to undergo primary TKA, THA, or TSA

You may not qualify if…

• Age < 18 years
• Pregnant or breastfeeding
• Non-English speaking
• Unable to give informed consent
• Previous open hip, knee or shoulder surgery
• Pre-determined patients discharging to ECF
• Patients with allergies to bupivacaine
• Patients currently taking opioid pain medication
• Patients with contraindication to nerve blocks
• Patients undergoing simultaneous bilateral joint replacement, as this would require >1 dose of liposomal bupivacaine (Exparel®) per patient for each surgical site
• Patients with severe hepatic disease
• Patients with chronic heart disease as defined as a decreased ejection fraction

Where it is running

• OhioHealth Riverside Methodist Hospital — Columbus, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.